These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34877897)

  • 21. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
    Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
    J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.
    Liu W; Zhu HM; Niu GJ; Shi EZ; Chen J; Sun B; Chen WQ; Zhou HG; Yang C
    Bioorg Med Chem; 2014 Jan; 22(1):292-302. PubMed ID: 24316352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virtual screening and molecular simulation study of natural products database for lead identification of novel coronavirus main protease inhibitors.
    Tripathi N; Goel B; Bhardwaj N; Sahu B; Kumar H; Jain SK
    J Biomol Struct Dyn; 2022 May; 40(8):3655-3667. PubMed ID: 33213294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fourteen immunomodulatory alkaloids and two prenylated phenylpropanoids with dual therapeutic approach for COVID-19: molecular docking and dynamics studies.
    Omar R; Abd El-Salam M; Elsbaey M; Hassan M
    J Biomol Struct Dyn; 2024 Mar; 42(5):2298-2315. PubMed ID: 37116054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
    Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
    In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.
    Ishola AA; Adedirin O; Joshi T; Chandra S
    Comput Biol Med; 2021 Jul; 134():104483. PubMed ID: 34020129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorine Atoms on C
    Chaves OA; Rodrigues-Santos CE; Echevarria Á; Sacramento CQ; Fintelman-Rodrigues N; Temerozo JR; Castro-Faria-Neto HC; Souza TMLE
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL
    Rao P; Shukla A; Parmar P; Rawal RM; Patel BV; Saraf M; Goswami D
    J Biomol Struct Dyn; 2022 Jan; 40(1):348-360. PubMed ID: 32875950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.
    Avti P; Chauhan A; Shekhar N; Prajapat M; Sarma P; Kaur H; Bhattacharyya A; Kumar S; Prakash A; Sharma S; Medhi B
    J Biomol Struct Dyn; 2022; 40(19):8894-8904. PubMed ID: 33998950
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Kumar B; Parasuraman P; Murthy TPK; Murahari M; Chandramohan V
    J Biomol Struct Dyn; 2022 Oct; 40(17):7796-7814. PubMed ID: 33759690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
    Kumar V; Roy K
    SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular docking and simulation studies of natural compounds of
    Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
    J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Iype E; Pillai U J; Kumar I; Gaastra-Nedea SV; Subramanian R; Saha RN; Dutta M
    J Biomol Struct Dyn; 2022; 40(23):12800-12811. PubMed ID: 34550861
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Kumar R; Kumar R; Tanwar P
    J Biomol Struct Dyn; 2022 Oct; 40(16):7394-7407. PubMed ID: 33715592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
    Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual screening of approved clinic drugs with main protease (3CL
    Wang Q; Zhao Y; Chen X; Hong A
    J Biomol Struct Dyn; 2022 Feb; 40(2):685-695. PubMed ID: 32909528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiazole-based SARS-CoV-2 protease (COV M
    Elsayed RW; Sabry MA; El-Subbagh HI; Bayoumi SM; El-Sayed SM
    Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200121. PubMed ID: 35607750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Novel Drug Candidates for the Inhibition of Catalytic Cleavage Activity of Coronavirus 3CL-like Protease Enzyme.
    Gurung AB; Al-Anazi KM; Ali MA; Lee J; Farah MA
    Curr Pharm Biotechnol; 2022; 23(7):959-969. PubMed ID: 34097590
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Khan PM; Kumar V; Roy K
    Comb Chem High Throughput Screen; 2021; 24(8):1281-1299. PubMed ID: 32928086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.